EP Patent

EP4215196A1 — Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor

Assigned to Abivax SA · Expires 2023-07-26 · 3y expired

What this patent protects

The present invention relates to A pharmaceutical combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, prodrug thereof or a metabolite thereof with a JAK inhibitor or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I…

USPTO Abstract

The present invention relates to A pharmaceutical combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, prodrug thereof or a metabolite thereof with a JAK inhibitor or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) has the following formula:It further relates to a pharmaceutical composition comprising said combination, its use and a pharmaceutical kit comprising it.

Drugs covered by this patent

Patent Metadata

Patent number
EP4215196A1
Jurisdiction
EP
Classification
—
Expires
2023-07-26
Drug substance claim
No
Drug product claim
No
Assignee
Abivax SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.